]
TB Innovations

Open Forum Series

The Open Forum Series engages regulatory authorities around the world to identify and address crucial issues involved in advancing new TB regimens to registration, and ultimately to the people who need them.

The 21st century has seen a dramatic upsurge in TB drug development — movement due, in part, to the TB Alliance and its partners. But these scientific advances have not significantly impacted the disease. New ways of developing cures require updated regulatory pathways. Engaging regulatory authorities during the TB drug development process is necessary to ensure new health technologies achieve maximal impact on the world’s TB burden.

The TB Alliance is engaging regulatory authorities around the world to create, advance, and harmonize the development of new guidelines for the evaluation, registration, and approval of new TB drug regimens. The Open Forum Series of conferences is designed to identify and address crucial issues involved achieving this goal.

Open Forum meetings bring together regulators, TB drug developers, and other interested stakeholders such as academics, TB care providers, public health policy-makers, and community advocates. The Open Forums are designed to encourage participation by representatives of regulatory agencies and National TB Control Programs from both major industrialized and high burden countries. These meetings also highlight key questions related to the development of novel combination therapies.

Click a link below for more information on Open Forum meetings:

Open Forum 4, August 18-19, 2010. Addis Ababa, Ethiopia.

Open Forum 3, May 5-6, 2008. New Delhi, India.

Open Forum 2, December 12-13, 2006. London, United Kingdom

Open Forum 2005, December 6-7, 2005, Arlington, United States